Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
Combinations of one or more dihydropyridine calcium channel blockers with mixtures of omega-3 fatty acids, methods of administering such combinations, and unit dosages of such combinations.
1 . A pharmaceutical composition comprising:
a. a unit dosage form comprising natural or synthetic omega-3 fatty acids or pharmaceutically acceptable esters, derivatives, conjugates, precursors or salts thereof, or mixtures thereof and optionally a solubilizer, and
b. one or more outer coatings on the unit dosage form, wherein at least one outer coating comprises one or more dihydropyridine calcium channel blockers,
c. optionally one or more barrier coatings between the unit dosage form and the one or more outer coatings, and
d. optionally a seal coating on the unit dosage form.
2 . The pharmaceutical composition of claim 1 , wherein one or more outer coatings is formulated for immediate release, delayed/enteric release or sustained release of the one or more dihydropyridine calcium channel blockers.
3 . The pharmaceutical composition of claim 1 , wherein one or more barrier coatings is formulated for enteric/delayed release of the natural or synthetic omega-3 fatty acids or pharmaceutically acceptable esters, derivatives, conjugates, precursors or salts thereof, or mixtures thereof, or as a nonfunctional protective layer.
4 . The pharmaceutical composition of claim 1 , wherein the unit dosage form is a soft gelatin capsule, a hard gelatin capsule, or a tablet.
5 . The pharmaceutical composition of claim 1 , wherein the one or more dihydropyridine calcium channel blockers are Bay K 8644, amlodipine, felodipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine and isradipine.
6 . The pharmaceutical composition of claim 5 , wherein the one or more dihydropyridine calcium channel blockers is isradipine.
7 . The pharmaceutical composition of claim 1 , comprising from about 0.5 mg to about 100 mg of one or more dihydropyridine calcium channel blockers.
8 . The pharmaceutical composition of claim 1 , wherein the omega-3 fatty acids contain at least about 70% EPA and DHA.
9 . The pharmaceutical composition of claim 1 , comprising about 0.1 g to about 10 g omega-3 fatty acids or pharmaceutically acceptable esters, derivatives, conjugates, precursors or salts thereof, or mixtures thereof.
10 . The pharmaceutical composition of claim 1 , wherein the at least one outer coating comprising one or more dihydropyridine calcium channel blockers is sprayed onto the unit dosage form while controlling the rate of coating deposition and controlling the temperature during the coating process to produce a physically and chemically stable coated unit dosage form.
11 . A pharmaceutical composition in unit dosage form, comprising a heterogeneous suspension or an essentially homogenous solution of one or more dihydropyridine calcium channel blockers in a solvent system comprising natural or synthetic omega-3 fatty acids or pharmaceutically acceptable esters, derivatives, conjugates, precursors or salts thereof, or mixtures thereof.
12 . The pharmaceutical composition of claim 11 , wherein the omega-3 fatty acids contain at least about 70% EPA and DHA.
13 . The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition comprises the heterogeneous suspension.
14 . The pharmaceutical composition of claim 13 , wherein at least about 80% of the one or more dihydropyridine calcium channel blockers are present as solid particles in the suspension.
15 . The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition comprises the essentially homogeneous solution.
16 . The pharmaceutical composition of claim 15 , wherein less than about 10% of the one or more dihydropyridine calcium channel blockers is undissolved in the solvent system.
17 . The pharmaceutical composition of claim 16 , wherein the solvent system further comprises at least one solubilizer in an amount of 50% or less w/w based on the total weight of the solvent system.
18 . The pharmaceutical composition of claim 15 , wherein no more than 10% of the dissolved one or more dihydropyridine calcium channel blockers precipitates out of the essentially homogenous solution when the pharmaceutical composition is stored at room temperature and 60% relative humidity for a period of at least one month.
19 . A method of treating a subject having one or more conditions selected from the group consisting of hypertriglyceridemia, hypercholesterolemia, hypertension, angina, coronary heart disease (CHD), vascular disease, artherosclerotic disease and related conditions, the prevention or reduction of cardiovascular and vascular events, and the reduction of insulin resistance, fasting glucose levels and postprandial glucose levels, comprising administering to the subject an effective amount of one or more dihydropyridine calcium channel blockers and natural or synthetic omega-3 fatty acids or pharmaceutically acceptable esters, derivatives, conjugates, precursors or salts thereof, or mixtures thereof.